 Global Blood Therapeutics Inc NASDAQ: GBT has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA NASDAQ: SNY. One program pursues a novel anti-sickling mechanism, and the other leverages a new approach to reduce inflammation and oxidative stress. 